Restart Life Stock Price, News & Analysis

Wellbeing Digital Sciences (OTC: KONEF, NEO: MEDI) announced that its subsidiary KGK Science will conduct a Phase II clinical trial to evaluate the effects of psilocybin on Fragile X syndrome. This marks the first research into psilocybin microdoses for improving behavioral and cognitive symptoms associated with the disorder. The trial, which will involve 10 participants, supports Nova Mentis’ drug development efforts under FDA Orphan Drug designation. Results are aimed at addressing significant unmet medical needs in treatment.

Nova Mentis Life Science Corp. has initiated patient enrollment for its North American Observational Study focusing on Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS). This study aims to develop a Diagnostic Index to enhance diagnosis and treatment of these conditions by analyzing neuroinflammatory profiles and serotonin levels in patients. The company plans to recruit at least 300 participants, including 200+ patients with ASD/FXS. Additionally, Nova has engaged consulting firms for marketing services and issued 1,250,000 stock options to marketing consultants.

Nova Mentis Life Science Corp. has completed a non-brokered private placement financing, raising $1,483,500. The company issued 29,670,000 units at CAD $0.05 each, with each unit including one common share and one warrant priced at CAD $0.075. Proceeds will fund the launch of an autism spectrum disorder observational study and a Phase 2A clinical study for fragile X syndrome, along with general working capital. All issued securities are subject to a four-month hold period.

Nova Mentis Life Science Corp. (NMLSF) announced successful results from a preclinical study on psilocybin microdoses for treating fragile X syndrome (FXS). Conducted at Rome Tre University, the study demonstrated that low doses of psilocybin improved cognitive defects in a genetic model of FXS, with the optimal dose being 0.1 mg/kg. The findings support advancing to a Phase 2A clinical trial in Canada. Additionally, Nova plans to raise up to $1 million through a private placement to fund these initiatives.

Nova Mentis Life Science Corp (NMLSF) and Mycrodose Therapeutics announced a significant milestone in merging NOVA's psilocybin-based drug development with Mycrodose's transdermal technology. Initial studies are being conducted in San Diego to ascertain effective skin delivery of psilocybin, targeting neuroinflammatory disorders like Fragile X Syndrome (FXS). This partnership aims to deliver microdoses via a transdermal patch, minimizing hallucinogenic effects for patients. NOVA has already completed four preclinical studies and received orphan drug designation for psilocybin in FXS from the U.S. and EU.

Nova Mentis Life Science Corp. (NMLSF) has filed a patent for a genetic diagnostic and therapeutic approach targeting neuroinflammatory diseases, including Fragile X syndrome and autism spectrum disorders. This innovative mRNA-based paradigm aims to assess therapeutic responses and facilitate the development of psilocybin-based treatments. Dr. Marvin S. Hausman emphasized the potential for breakthrough products in psychedelic medicine. Nova is the first biotech firm to secure psilocybin orphan drug designation in the U.S. and EU, aiming to address chronic conditions with significant unmet medical needs.

Nova Mentis Life Science Corp. has received approval from the U.S. FDA for its psilocybin drug's Orphan Drug Application targeting Fragile X Syndrome (FXS), the leading inherited cause of autism. This designation grants NOVA significant benefits, including seven to ten years of market exclusivity and eligibility for federal tax credits. Notably, NOVA is the first biotech firm to have psilocybin recognized for FXS treatment by both FDA and EMA. The company plans to initiate phase 2 clinical studies supported by real-world evidence data.

Nova Mentis Life Science Corp. (NMLSF) announced it received orphan drug designation from the European Medicines Agency for its psilocybin drug targeting fragile X syndrome (FXS), a leading genetic cause of autism spectrum disorder. This designation accelerates the drug approval process, providing benefits like ten years of market exclusivity and grants. CEO Will Rascan emphasized the milestone's significance for advancing clinical programs in Europe, aiming for a phase 2 study. Currently, there are no effective treatments for FXS, making this development a critical step toward addressing an unmet medical need.

Nova Mentis Life Science Corp. has partnered with Mycrodose Therapeutics to develop patented products targeting neuroinflammatory disorders, including fragile X syndrome and autism spectrum disorder. This collaboration aims to leverage Mycrodose's advanced drug delivery systems and NOVA's psilocybin therapeutic, which has shown promising preclinical results. The partnership could broaden the patient base for psilocybin treatments, especially in pediatric applications. NOVA has applied for Orphan Drug designation, providing significant financial and regulatory benefits.